MAVERICK NDLOVU
Default profile image
----------

BLOG #10

24 Apr 2021, 17:13 Publicly Viewable
  1. Dopamine agonists and anticholinergic drugs
  2. It increases the synthesis of dopamine, the release of dopamine and prevents dopamine re-uptake.
  3. MAO B Inhibitors prevent the metabolism of dopamine by MAO B. Amantadine and istradefyllin are Adenosine A2A antagonist and prevent adenosine from metabolising dopamine. COMT inhibitors prevent COMT from converting levodopa to 3-O-methyldopa.
  4. Bromocriptine is a dopamine agonist and pramipexole and ropinirole are not.
  5. Bromocriptine and ropinirole are dopamine 2 agonists and pramipexole is a dopamine 3 agonist.
  6. Pramipexole and Rasagiline. Pramipexole acts as a scavenger for hydrogen peroxide and Rasagiline prevents MPTP-mediated Parkinson’s.
  7. They have neuroprotective effects and they decrease disease progression.
  8. COMT inhibitors act by preventing the conversion of levodopa to 3-O-Methyldopa. They decrease fluctuations, improve response and prolong on-times.
  9. Istradefyllin acts by antagonizing denosine A2A.
  10. Safinamide is a MAO B inhibitor that increases dopamine levels by preventing re-uptake and also decreases glutamate release.